POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)
Latest Information Update: 08 Jun 2025
At a glance
- Drugs GNT I122 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms POLARIS
- Sponsors GentiBio
Most Recent Events
- 11 Apr 2025 Status changed from planning to not yet recruiting.
- 07 Oct 2024 New trial record
- 30 Sep 2024 According to a GentiBio media release, GNTI-122 will enter the clinic in 2025.